Transforming patients’ lives by leading innovation in nuclear medicine

Global cancer care
Virtual #ASCO20
AAA is going digital!

Our Work

Our work is guided by our commitment to bring new innovations to patients.

AAA is developing a pipeline of nuclear medicine theragnostic pairings for oncology indications. Our theragnostic platform involves radiolabeling a targeting molecule with fluorine 18 (F-18), gallium 68 (Ga-68), or other radionuclides used for precision radioligand imaging, or with lutetium 177 (Lu-177), actinium 225 (Ac-225) or other radionuclides used for treatment to create a targeted radioligand therapy.

Our other products include radiopharmaceuticals for molecular imaging with Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Looking For Clinical Trials?

Find a clinical trial in your area

As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to diagnose and treat disease.

nuclear medicine clinical trials

Wistia video thumbnail

AAA is Innovating Against Cancer

Apr 7, 2020

Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT®…

Mar 25, 2020

Advanced Accelerator Applications Announces Start of Phase III Study Investigating Radioligand Therapy Lutathera®…

Jul 29, 2019

Advanced Accelerator Applications Announces State of Israel Ministry of Health Approval for Lutathera®…

Jun 5, 2019

Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®…

by @adacap_news
RT @NovartisNews: We are honored that the Boston Consulting Group has ranked Novartis among the 50 most innovative companies in the world.…